View in EDS HTML Full Text PDF Full Text

A meta-analysis evaluating effects of the rotigotine in Parkinson's disease, focusing on sleep disturbances and activities of daily living.

Saved in:

Bibliographic Details
Title:	A meta-analysis evaluating effects of the rotigotine in Parkinson's disease, focusing on sleep disturbances and activities of daily living.
Authors:	Sun, Weibo (AUTHOR), Wang, Qingyong (AUTHOR), Yang, Tiansong (AUTHOR), Feng, Chuwen (AUTHOR), Qu, Yuanyuan (AUTHOR), Yang, Yan (AUTHOR), Li, Chaoran (AUTHOR), Sun, Zhongren (AUTHOR), Asakawa, Tetsuya (AUTHOR)
Source:	Neurological Sciences. Oct2022, Vol. 43 Issue 10, p5821-5837. 17p. 1 Diagram, 4 Charts, 3 Graphs.
Subjects:	Drug therapy for Parkinson's disease, Sulfur compounds, Dopamine agonists, Clinical trials, Meta-analysis, Activities of daily living, Sleep, Hydrocarbons, Parkinson's disease, Research funding, Disease complications
Abstract:	Background: Rotigotine transdermal patch (TP) is a useful dopaminergic medication for Parkinson's disease (PD). This meta-analysis attempted to evaluate the effects of rotigotine TP on motor performance, activities of daily living (ADL) limitations, and sleep disturbances in patients with PD.Methods: Only randomized controlled clinical trials (RCTs) with placebo design were included in this study. The clinical outcomes, evaluated using the Unified Parkinson's Disease Rating Scale (UPDRS III), UPDRS-II, UPDRS Part II + III, Parkinson's Disease Sleep Scale (PDSS)-2, and adverse events (AEs) were evaluated. The Jadad scale was used to evaluate study quality.Results: A total of 16 RCTs with 4682 patients with PD were enrolled in this study. We found that rotigotine TP significantly reduced the UPDRS-III, UPDRS-II, and UPDRS Part II + III scores, indicating that rotigotine TP led to a significant amelioration of movement symptoms and ADL limitations. Moreover, we found that rotigotine TP significantly reduced PDSS-2 scores, suggesting that rotigotine TP led to a remarkable improvement in sleep quality. Meanwhile, compared with the placebo group, patients taking rotigotine TP did not have added incidence of AEs.Conclusion: This study verified the efficacy and safety of rotigotine TP in treating PD. The findings of the present study provide compelling evidence concerning and insight into clinical usage of rotigotine TP. Future studies will focus on more non-motor symptoms affected by rotigotine TP. [ABSTRACT FROM AUTHOR]
	Copyright of Neurological Sciences is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database:	Psychology and Behavioral Sciences Collection
Full text is not displayed to guests. Login for full access.

Be the first to leave a comment!